Skip to content

Latest news

Årsstämman för Athera beslutar att bolaget skall träda i frivillig likvidation (Swedish only)

Resultaten av den kliniska studien i hjärtinfarkt har givit visst stöd för effekt av behandlingen med ATH3G10, samt överlag god säkerhet. Dock har en oväntat hög frekvens av immunogenicitet påvisats och beredningsformen kan inte tas vidare kliniskt utan modifieringar. Alternativet till likvidation skulle kräva utveckling av en helt ny antikropp, vilket inte ses som kommersiellt försvarbart.

Press contacts

James Hall

James Hall

Press contact Chief Executive officer; MD, PhD Chief Executive officer; MD, PhD +46705775300
Carina Schmidt

Carina Schmidt

Press contact Senior Business Advisor, M.Sc. Senior Business Advisor, M.Sc. +46 (0)76-1938190

Clinical stage development of anti-inflammatory antibody therapeutics for treatment of immunovascular disease

Athera is a clinical stage biopharmaceutical company focused on developing targeted anti-inflammatory biological candidate drugs and companion diagnostics for the prevention and treatment of immunovascular disease. The Company initiated its current program in 2005, harnessing breakthrough innovations made at the world-renowned Karolinska Institutet, Sweden. The company currently has a proprietary clinical development stage program, PC-mAb, supported by an approved proprietary companion diagnostic kit. Future development costs for the antibody therapy will be co-financed by the EU FP7 program, in the project CARDIMMUN. Athera is managed by a core team of senior professionals from the pharmaceutical and diagnostics industries in a semi-virtual organization.

Athera Biotechnologies AB
Sankt Eriksgatan 117, 4th floor
11343 Stockholm
Sweden
Visit our other newsrooms